Corpus ID: 218840767

Evaluation of LIQ861 Inhalation Powder Deposition and Pharmacokinetics

@inproceedings{Maynor2020EvaluationOL,
  title={Evaluation of LIQ861 Inhalation Powder Deposition and Pharmacokinetics},
  author={Benjamin W. Maynor and S A Anderson and Toby Vaughn and Philippe Brudi and Cedric Van Holsbeke and Charles Mussche and Benjamin Mignot and Robert F. Roscigno},
  year={2020}
}
Inhaled prostacyclin (PGI) therapies offer significant important clinical benefits to patients with Pulmonary Arterial Hypertension (PAH), compared to other PGI delivery routes. Current approved PGI inhaled therapies are delivered using nebulization, which can present a treatment burden on patients. For instance, Tyvaso® (treprostinil inhalation solution, United Therapeutics, Silver Spring, MD) uses a pulsed, ultrasonic nebulizer delivering approximately 6 mcg of treprostinil per breath, with a… Expand
1 Citations

Figures and Tables from this paper

Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension
TLDR
Re-formulation efforts to develop a more convenient solution-based metered-dose inhaler (MDI) formulation of TP are reported on, with a promising formulation that demonstrates uniform in vitro drug delivery, a PK profile suitable for a once-daily administration, efficacy lasting at least 12 h in a hypoxic challenge model, and a significantly higher cough threshold than the parent drug treprostinil. Expand

References

SHOWING 1-5 OF 5 REFERENCES
A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration
TLDR
The intent of this review is to outline pharmacokinetic considerations of the three treprostinil formulations and provide clinicians with a resource that may support clinical decisions in treating patients with PAH. Expand
INSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH) [presentation
  • In ISHLT 39th Annual Meeting & Scientific Sessions
  • 2019
Preclinical and Phase 1 Clinical Characterization of LIQ861, a New Dry Powder Formulation of Treprostinil [poster]. In: World Symposium on Pulmonary Hypertension
  • 2018
Preclinical and Phase 1 Clinical Characterization of LIQ861, a New Dry Powder Formulation of Treprostinil [poster
  • World Symposium on Pulmonary Hypertension
Tyvaso Prescribing Information